176 related articles for article (PubMed ID: 10603070)
1. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
Kasper S; Hale A; Azorin JM; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 2():II1-II14. PubMed ID: 10603070
[No Abstract] [Full Text] [Related]
2. Comparative effectiveness of antipsychotic drugs.
Meibach RC
Am J Psychiatry; 2003 Mar; 160(3):589-90; author reply 592-3. PubMed ID: 12611851
[No Abstract] [Full Text] [Related]
3. [Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Hilger E; Kasper S
Wien Klin Wochenschr; 2000 Dec; 112(24):1031-8. PubMed ID: 11204312
[TBL] [Abstract][Full Text] [Related]
4. The promise of new drugs for schizophrenia treatment.
Tamminga CA
Can J Psychiatry; 1997 Apr; 42(3):265-73. PubMed ID: 9114942
[TBL] [Abstract][Full Text] [Related]
5. Novel antipsychotics: comparison of weight gain liabilities.
Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR
J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912
[TBL] [Abstract][Full Text] [Related]
6. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia.
Kasper S
Int Clin Psychopharmacol; 1998 Nov; 13(6):253-62. PubMed ID: 9861575
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine, sertindole and schizophrenia.
Drug Ther Bull; 1997 Nov; 35(11):81-3. PubMed ID: 9464002
[No Abstract] [Full Text] [Related]
8. Atypical antipsychotics and cognition in schizophrenia.
Sharma T
Arch Gen Psychiatry; 2002 Jun; 59(6):571-2; author reply 573-5. PubMed ID: 12044209
[No Abstract] [Full Text] [Related]
9. Comparative effectiveness of antipsychotic drugs.
Messori A
Am J Psychiatry; 2003 Mar; 160(3):591-2; author reply 592-3. PubMed ID: 12611854
[No Abstract] [Full Text] [Related]
10. Olanzapine and risperidone.
Love RC; Kelly DL
Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
[No Abstract] [Full Text] [Related]
11. The new generation of antipsychotic drugs.
Tamminga CA; Lahti AC
Int Clin Psychopharmacol; 1996 May; 11 Suppl 2():73-6. PubMed ID: 8803664
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
Leucht S; Pitschel-Walz G; Abraham D; Kissling W
Schizophr Res; 1999 Jan; 35(1):51-68. PubMed ID: 9988841
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine-induced reversible priaprism: a case report.
Deirmenjian JM; Erhart SM; Wirshing DA; Spellberg BJ; Wirshing WC
J Clin Psychopharmacol; 1998 Aug; 18(4):351-3. PubMed ID: 9690708
[No Abstract] [Full Text] [Related]
14. Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.
Kasper S; Küfferle B
J Clin Psychopharmacol; 1998 Aug; 18(4):353-6. PubMed ID: 9690709
[No Abstract] [Full Text] [Related]
15. Drug metabolism and atypical antipsychotics.
Prior TI; Chue PS; Tibbo P; Baker GB
Eur Neuropsychopharmacol; 1999 Jun; 9(4):301-9. PubMed ID: 10422890
[TBL] [Abstract][Full Text] [Related]
16. The effects of risperidone and olanzapine on the indications for clozapine.
Ganguli R; Brar JS
Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
[TBL] [Abstract][Full Text] [Related]
17. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
Gureje O; Miles W; Keks N; Grainger D; Lambert T; McGrath J; Tran P; Catts S; Fraser A; Hustig H; Andersen S; Crawford AM
Schizophr Res; 2003 Jun; 61(2-3):303-14. PubMed ID: 12729882
[TBL] [Abstract][Full Text] [Related]
19. Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
Bouchard RH; Demers MF; Simoneau I; Alméras N; Villeneuve J; Mottard JP; Cadrin C; Lemieux I; Després JP
J Clin Psychopharmacol; 2001 Feb; 21(1):110-1. PubMed ID: 11199934
[No Abstract] [Full Text] [Related]
20. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment.
Crocq MA; Leclercq P; Guillon MS; Bailey PE
Eur Psychiatry; 2002 Sep; 17(5):296-7. PubMed ID: 12381502
[No Abstract] [Full Text] [Related]
[Next] [New Search]
